Astrazeneca plc ADR [NASDAQ: AZN] gained 1.40% on the last trading session, reaching $71.81 price per share at the time.
Astrazeneca plc ADR represents 3.10 billion in outstanding shares, while the company has a total market value of $222.71 billion with the latest information. AZN stock price has been found in the range of $71.3 to $72.46.
If compared to the average trading volume of 4.75M shares, AZN reached a trading volume of 4045505 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Astrazeneca plc ADR [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $93.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.37. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Exane BNP Paribas have made an estimate for Astrazeneca plc ADR shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 15, 2025. The new note on the price target was released on February 13, 2025, representing the official price target for Astrazeneca plc ADR stock.
The Price to Book ratio for the last quarter was 5.43, with the Price to Cash per share for the same quarter was set at 1.74. Price to Free Cash Flow for AZN in the course of the last twelve months was 19.42 with Quick ratio for the last quarter at 0.70.
Trading performance analysis for AZN stock
Astrazeneca plc ADR [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.96. With this latest performance, AZN shares dropped by -1.64% in over the last four-week period, additionally plugging by 7.44% over the last 6 months – not to mention a rise of 9.60% in the past year of trading.
Astrazeneca plc ADR [AZN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Astrazeneca plc ADR [AZN] shares currently have an operating margin of 20.63% and a Gross Margin at 72.58%. Astrazeneca plc ADR’s Net Margin is presently recorded at 14.14%.
Return on Equity for this stock inclined to 7.45%, with Return on Assets sitting at 7.45%.
Astrazeneca plc ADR [AZN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Astrazeneca plc ADR go to 11.42%.
An analysis of Institutional ownership at Astrazeneca plc ADR [AZN]
There are presently around $17.08%, or 17.08% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 64.94 million shares, which is approximately 4.1788%. PRIMECAP MANAGEMENT CO/CA/, holding 42.6 million shares of the stock with an approximate value of $$3.32 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $$3.16 billion in AZN stock with ownership which is approximately 2.6106%.
